💰 It’s worth €500,000 ($574,000) and aims to boost oncology service innovations.
🚀 The initiative targets biotechs developing recombinant protein-based cancer therapies.
🗓️ Winners will gain credits for Mabion’s CDMO capabilities.
🤝 The contest promotes collaboration, encouraging innovators to accelerate their projects.
🔗 More details are available online.
Introduction:
Mabion, a Contract Development and Manufacturing Organization (CDMO) based in Poland, has initiated a €500,000 contest to encourage innovations in the development of recombinant protein-based therapies for cancer. This initiative aims to bridge funding gaps faced by biotech companies, particularly those at the forefront of oncology advancements.
- The contest is focused on enhancing the development of novel oncology treatments and will culminate at CPHI Worldwide in Frankfurt, showcasing promising biotech innovations.
- Mabion’s COO, Dr. Julita Balcerek, emphasized that the initiative not only offers financial support but also an opportunity for collaboration with experienced partners in the field.
- The submission process is designed to be accessible, utilizing QR codes for entry at industry conventions, and providing applicants with guidance from Mabion’s business development team.
- Entries will be evaluated by an independent jury based on scientific merit, feasibility, and anticipated impact on patients, with the winner receiving significant funding towards Mabion’s integrated CDMO capabilities.
- The contest is part of a broader marketing strategy that includes promotions across various platforms such as LinkedIn and direct engagement at BIO and CPHI, ensuring continuous visibility throughout the initiative.
Conclusion:
Mabion’s €500,000 contest represents an innovative approach to supporting and accelerating oncology research and development. By addressing financial barriers and fostering collaborative partnerships, Mabion aims to facilitate breakthroughs in cancer therapies and propel promising biotechnological innovations into the clinic. The initiative is indicative of a growing trend in the industry to enhance support for scientific advancements in oncology.
